Literature DB >> 16960916

Lentiviral vector integration sites in human NOD/SCID repopulating cells.

Stephanie Laufs1, Guillermo Guenechea, Africa Gonzalez-Murillo, K Zsuzsanna Nagy, M Luz Lozano, Coral del Val, Sunitha Jonnakuty, Agnes Hotz-Wagenblatt, W Jens Zeller, Juan A Bueren, Stefan Fruehauf.   

Abstract

BACKGROUND: Recent observations of insertional mutagenesis in preclinical and clinical settings emphasize the relevance of investigating comprehensively the spectrum of integration sites targeted by specific vectors.
METHODS: We followed the engraftment of lentivirally transduced human cord blood (CB) progenitor cells after transplantation into NOD/SCID mice using a self-inactivating HIV-1-derived vector expressing the enhanced green fluorescent protein (EGFP).
RESULTS: The mean of transduction of CD34(+) CB cells was 41%, as deduced from the percentage of EGFP(+) cells before transplantation. At 3 weeks post-transplantation, the average of EGFP(+) cells in the human cell population was 65 +/- 8%, and increased to 75 +/- 10% at 12 weeks post-transplantation. In order to determine the proviral integration sites in human NOD/SCID repopulating cells (SRCs) we used the ligation-mediated polymerase chain reaction (LM-PCR) technique. Sixty-eight percent of the integrations were found to be located in RefSeq genes, most of them in intron regions. Twenty percent of these integrations occurred within a distance of 10 kb from the transcription start site; a percentage that is significantly lower compared to that observed in cells transduced by gammaretroviral vectors. Sixty-two percent of integrations occurred in genes with a biological function in cell metabolism, and four integrations were located in genes with a role in tumorigenesis.
CONCLUSIONS: These investigations indicate that integration of lentiviral vectors in human repopulating cells capable of engrafting NOD/SCID mice preferentially occur in coding regions of the human genome. Nevertheless, the clustering of integrations at the transcriptional start is not as high as that observed for gammaretroviral vectors. Copyright (c) 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960916     DOI: 10.1002/jgm.958

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  12 in total

1.  Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors.

Authors:  Africa Gonzalez-Murillo; M Luz Lozano; Eugenio Montini; Juan A Bueren; Guillermo Guenechea
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

Review 2.  Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors.

Authors:  Elena Herrera-Carrillo; Ying Poi Liu; Ben Berkhout
Journal:  Hum Gene Ther Methods       Date:  2017-08       Impact factor: 2.396

3.  Lentiviral vector integration profiles differ in rodent postmitotic tissues.

Authors:  Cynthia C Bartholomae; Anne Arens; Kamaljit S Balaggan; Rafael J Yáñez-Muñoz; Eugenio Montini; Steven J Howe; Anna Paruzynski; Bernhard Korn; Jens Uwe Appelt; Angus Macneil; Daniela Cesana; Ulrich Abel; Hanno Glimm; Luigi Naldini; Robin R Ali; Adrian J Thrasher; Christof von Kalle; Manfred Schmidt
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

4.  Efficiency and safety of O⁶-methylguanine DNA methyltransferase (MGMT(P140K))-mediated in vivo selection in a humanized mouse model.

Authors:  Ruhi Phaltane; Reinhard Haemmerle; Michael Rothe; Ute Modlich; Thomas Moritz
Journal:  Hum Gene Ther       Date:  2014-01-07       Impact factor: 5.695

5.  Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector.

Authors:  P S Becker; J A Taylor; G D Trobridge; X Zhao; B C Beard; S Chien; J Adair; D B Kohn; J E Wagner; A Shimamura; H-P Kiem
Journal:  Gene Ther       Date:  2010-05-20       Impact factor: 5.250

6.  Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme.

Authors:  Nestor W Meza; Maria E Alonso-Ferrero; Susana Navarro; Oscar Quintana-Bustamante; Antonio Valeri; Maria Garcia-Gomez; Juan A Bueren; Jose M Bautista; Jose C Segovia
Journal:  Mol Ther       Date:  2009-09-15       Impact factor: 11.454

Review 7.  Sites of retroviral DNA integration: From basic research to clinical applications.

Authors:  Erik Serrao; Alan N Engelman
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-10-28       Impact factor: 8.250

Review 8.  Development of lentiviral gene therapy for Wiskott Aldrich syndrome.

Authors:  Anne Galy; Maria-Grazia Roncarolo; Adrian J Thrasher
Journal:  Expert Opin Biol Ther       Date:  2008-02       Impact factor: 4.388

Review 9.  MicroRNAs as therapeutic targets in breast cancer metastasis.

Authors:  Fahima Danesh Pouya; Yousef Rasmi; Maria Gazouli; Eleni Zografos; Mohadeseh Nemati
Journal:  Drug Deliv Transl Res       Date:  2021-05-13       Impact factor: 4.617

10.  LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives.

Authors:  Faisal A Al-Allaf; Charles Coutelle; Simon N Waddington; Anna L David; Richard Harbottle; Michael Themis
Journal:  Int Arch Med       Date:  2010-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.